Cantor Fitzgerald Reiterates Overweight on Bicara Therapeutics, Maintains $13.01 Price Target

Benzinga · 03/13 15:49
Cantor Fitzgerald analyst Eric Schmidt reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Overweight and maintains $13.01 price target.